
    
      Patients enrolled in NCT0031361, NYU 03-67 (A Phase II study of Oxaliplatin combined with
      continuous infusion topotecan as chemotherapy for patients with previously treated ovarian
      cancer NCI #6317) will receive oxaliplatin 85mg/m2 as a 2-hr IV infusion on D1, 15 and
      topotecan 0.4mg/m2/day as a continuous infusion for 14 days beginning on D1 (D1-15) on a 4
      week cycle.

      On days 1 and 15 of the first cycle, patients will also receive IV ondansetron 32 mg and 10mg
      of dexamethasone. Emend 125 mg will be given on day 1; on days 2-17, patients will be given
      daily oral 80mg Emend without dexamethasone.

      On cycles 2-6 patients opting to continue to receive Emend as above: Emend 125 mg will be
      given on day 1; on days 2-17, patients will be given daily oral 80mg Emend without
      dexamethasone.

      Following cycle 1, Emend will be given in its conventional schedule (i.e., d 1-3, and d
      15-17) unless after discussion with the Principal Investigator, the patient's request to
      receive drug as in cycle 1 is deemed desirable and safe to enter the optional extension arm.
    
  